Biomarin buying rare disease company Amicus for $4.8B
Biomarin buying rare disease company Amicus for $4.8B
Body unavailable. Use the original source.
Biomarin buying rare disease company Amicus for $4.8B
A compact weekly email covering company moves, product signals, regulatory updates, and notable funding.